Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: Health Minister Olivier Veran told a briefing he could not determine at this stage when the lockdown would end. If the government were to follow the scientific council’s advice, France would remain at a virtual standstill until April 28. A statement by the council, which advises President Emmanuel Macron on the coronavirus crisis, also said the lockdown was the only really efficient strategy at the moment and “needs to be strictly implemented”. Prime Minister Edouard Philippe said on Monday the widespread lockdown in France could last several more weeks and his government was tightening restrictions on daily life even further. Veran also said France would heed World Health Organization recommendations to increase coronavirus testing. Health agency chief Jerome Salomon said later France would soon be able to conduct 10,000 tests a day. Salomon reported 240 new deaths from coronavirus on Tuesday for a total of 1,100, an increase of 28% that made France the fifth nation to cross the 1,000-fatalities threshold after - China, Italy, Iran and Spain. This tally only accounts for people who died in public hospitals, whereas several retirement homes have been reporting deaths in the double digits. Salomon said health authorities would soon be able to tabulate data coming from retirement homes, which will likely trigger a more dramatic increase in registered fatalities. He said the total number of infections in France had risen to 22,300, a 12% jump in 24 hours. Salomon added that 2,516 people were in a serious condition requiring life support, up by 21% from Monday, and that 8,000 hospital beds were now equipped with ventilators. Claim: French coronavirus death toll tops 1,000, lockdown likely to be extended.

Output: France became the fifth country to report more than 1,000 deaths from coronavirus on Tuesday and a government body dealing with the outbreak suggested the national lockdown imposed last week for an initial 15 days should last at least six weeks.


Input: Consider Input: Paragraph: Scientists led by Ali Erturk at Ludwig Maximilians University in Munich have developed a technique that uses a solvent to make organs such as the brain and kidneys transparent. The organ is then scanned by lasers in a microscope that allows researchers to capture the entire structure, including the blood vessels and every single cell in its specific location. Using this blueprint, researchers print out the scaffold of the organ. They then load the 3D printer with stem cells which act as “ink” and are injected into the correct position making the organ functional. While 3D printing is already used widely to produce spare parts for industry, Erturk said the development marks a step forward for 3D printing in the medical field. Until now 3D-printed organs lacked detailed cellular structures because they were based on images from computer tomography or MRI machines, he said. “We can see where every single cell is located in transparent human organs. And then we can actually replicate exactly the same, using 3D bioprinting technology to make a real functional organ,” he said. “Therefore, I believe we are much closer to a real human organ for the first time now.”  Erturk’s team plan to start by creating a bioprinted pancreas over the next 2-3 years and also hope to develop a kidney within 5-6 years. The researchers will first test to see whether animals can survive with the bioprinted organs and could start clinical trials within 5-10 years, he said. Claim: German scientists create see-through human organs.

Output: Researchers in Germany have created transparent human organs using a new technology that could pave the way to print three-dimensional body parts such as kidneys for transplants.


Input: Consider Input: Paragraph: Kudos! This story reported on the costs of the drug Lucentis as well as the less expensive Avastin. The story provided quantitative information about the possible impact on vision. But we wish there information about any measurement of  the patients’ perspective on whether they are functioning better after receiving this treatment versus standard treatment While the story did include the common side effect of the drug in the study, there were other potentially important complications that were not mentioned. The story mentioned that the results reported on were from a phase III clinical trial; it included information about the number of affected eyes included in the study, and the impact on vision. The story did not engage in overt disease mongering. Several experts in the field were quoted in this story. In presenting the outcome of the study, the story mentioned in passing treatments currently used for treating diabetic macular edema. The story also mentioned the existence of another drug, Avastin, which was reported as working the same way as the study medication. (A more accurate description comparing Avastin and Lucentis is that they contain the nearly identical active ingredient but the production methods are a little different.) It would have been nice to mention that there is an on-going trial comparing the effectiveness of these two medications for the treatment of macular degeneration (not the condition which was the disease in the study reported on.) The story was crystal clear that the drug reported on, Lucentis, is available as it is FDA approved for another condition; the story also mentioned that it is not yet FDA approved for treatment of diabetic macular edema. The story was very clear that this was a new use for a medication that is already on the market. The story provided some insight that the company underwriting the costs of this study had a very similar but less expensive drug which was FDA approved for other use. It would have been useful to include a little more information comparing the two medications. It might also have been nice to include some information about how the drug studied works as compared to laser treatment, the current standard. Does not appear to rely on a press release. Claim: A Genentech Eye Treatment Is Found to Help Prevent Vision Loss in Diabetics


Output: This story reports on the results of a newly published phase III trial demonstrating the benefits of the drug Lucentis for vision in those with diabetic macular edema. While including pertinent information about the possible benefits, harms, and costs, the story also included some information about another very similar medication available at lower cost. It raises important questions about the possible impact of corporate sponsorship of clinical trials. That’s something the other two stories didn’t do. In the study reported on, not only did the company supply its more expensive drug for use in the study, they contributed $9 million dollars to run the study with the caveat that the less expensive form of the molecular not be included in the study. While it is exciting to have a new treatment for diabetic macular edema, it seems unfortunate not to study both medications to determine whether the more expensive one really adds value. With promising results attributable to the more expensive medication it becomes almost impossible for government and commercial payors to not cover it. It is precisely these sorts of studies that have driven health care costs in our country beyond a sustainable level.